Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (321-330 of 483) with videos related to

Pageof 49
Sort By:
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trialsBoris Böll, Helen Görgen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
European Journal of Cancer (Oxford, England : 1990)|May 5, 2021
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysisJakob M Riedl, Florian Posch, Lena Horvath, et al.
The Lancet. Infectious Diseases|September 17, 2021
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialFlorence Ader, Maude Bouscambert-Duchamp, Maya Hites, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Pageof 49

Showing results (321-330 of 483) with videos related to

Sort By:
Pageof 49
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trialsBoris Böll, Helen Görgen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
European Journal of Cancer (Oxford, England : 1990)|May 5, 2021
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysisJakob M Riedl, Florian Posch, Lena Horvath, et al.
The Lancet. Infectious Diseases|September 17, 2021
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialFlorence Ader, Maude Bouscambert-Duchamp, Maya Hites, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Pageof 49